You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
McKinsey
McKesson
Colorcon
Baxter

Last Updated: December 2, 2023

Sun Pharm Inds Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for SUN PHARM INDS INC, and when can generic versions of SUN PHARM INDS INC drugs launch?

SUN PHARM INDS INC has ninety-four approved drugs.

There are two US patents protecting SUN PHARM INDS INC drugs. There are two tentative approvals on SUN PHARM INDS INC drugs.

There are three patent family members on SUN PHARM INDS INC drugs in three countries and one hundred and twenty-six supplementary protection certificates in sixteen countries.

Summary for Sun Pharm Inds Inc
International Patents:3
US Patents:2
Tradenames:80
Ingredients:77
NDAs:94

Drugs and US Patents for Sun Pharm Inds Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Inc RISPERIDONE risperidone TABLET;ORAL 078036-002 Mar 10, 2014 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Sun Pharm Inds Inc CETIRIZINE HYDROCHLORIDE ALLERGY cetirizine hydrochloride TABLET, CHEWABLE;ORAL 077631-004 Jan 11, 2008 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Sun Pharm Inds Inc DEXMETHYLPHENIDATE HYDROCHLORIDE dexmethylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206734-008 Nov 5, 2021 AB RX No No ⤷  Try a Trial ⤷  Try a Trial
Sun Pharm Inds Inc METHYLPHENIDATE HYDROCHLORIDE methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 217229-001 Aug 25, 2023 AB RX No No ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Sun Pharm Inds Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sun Pharm Inds Inc ULTRAVATE halobetasol propionate CREAM;TOPICAL 019967-001 Dec 27, 1990 4,619,921 ⤷  Try a Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-002 May 25, 2012 9,089,534 ⤷  Try a Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-002 May 25, 2012 8,367,102 ⤷  Try a Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-004 May 25, 2012 8,952,064 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for SUN PHARM INDS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 20 mg ➤ Subscribe 2013-01-07
➤ Subscribe Capsules 35 mg ➤ Subscribe 2015-11-25
➤ Subscribe Capsules 30 mg and 40 mg ➤ Subscribe 2012-12-31
➤ Subscribe Capsules 20 mg ➤ Subscribe 2013-06-19
➤ Subscribe Capsules 25 mg ➤ Subscribe 2016-05-16

Supplementary Protection Certificates for Sun Pharm Inds Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1261586 15/2012 Austria ⤷  Try a Trial PRODUCT NAME: KOMBINATIONSPRODUKT VON SAXAGLIPTIN UND METFORMIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON, BEINHALTEND DIE HYDROCHLORIDSALZE VON SAXAGLIPTIN UND METFORMIN; REGISTRATION NO/DATE: EU/1/11/731/001-EU/1/11/731/012 20111124
0502314 C300478 Netherlands ⤷  Try a Trial PRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN AMLODIPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER AMLODIPINEBESILAAT; REGISTRATION NO/DATE: EU/1/10/648/001-028 20101007
1506211 C01506211/02 Switzerland ⤷  Try a Trial PRODUCT NAME: DAPAGLIFLOZIN + METFORMIN; REGISTRATION NO/DATE: SWISSMEDIC 65377 16.07.2015
2435024 132021000000095 Italy ⤷  Try a Trial PRODUCT NAME: UNA COMBINAZIONE DI FORMOTEROLO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI), GLICOPIRROLATO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI) E BUDESONIDE (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI)(TRIXEO AEROSPHERE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1498, 20201210
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Dow
Colorcon
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.